Search research articles
Contact Us
Filters
Showing results (71-80 of 181) with videos related to
Page
of 19
Sort By:
The Journal of Antimicrobial Chemotherapy
|
September 4, 2016
Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients
Adrian Curran, Jhon Rojas, Alfonso Cabello, et al.
AIDS Research and Human Retroviruses
|
December 21, 2010
Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults
Elena Ferrer, Luis del Rio, Esteban Martínez, et al.
AIDS (London, England)
|
April 21, 2011
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent
Jing Yuan, Sheng Guo, David Hall, et al.
HIV Clinical Trials
|
August 28, 2007
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response
Daniel Podzamczer, Martin S King, Cheri E Klein, et al.
Antiviral Therapy
|
March 1, 2012
Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial
Adrian Curran, Esteban Martinez, Daniel Podzamczer, et al.
HIV Medicine
|
April 27, 2011
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study)
Daniel Podzamczer, J Andrade-Villanueva, B Clotet, et al.
The Journal of Antimicrobial Chemotherapy
|
December 20, 2014
Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial
José Moltó, Marta Valle, Elena Ferrer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 15, 2015
The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial
José R Santos, María Saumoy, Adrian Curran, et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology
|
May 25, 2021
Comparison of two sample collection devices for anal cytology in HIV-positive men who have sex with men: Cytology brush and Dacron swab
Ana C Silva-Klug, Maria Saumoy, Nuria Baixeras, et al.
AIDS (London, England)
|
January 27, 2007
Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients
Esteban Martínez, Juan A Arnaiz, Daniel Podzamczer, et al.
Page
of 19
Search research articles
Search
Showing results (71-80 of 181) with videos related to
Sort By:
Page
of 19
The Journal of Antimicrobial Chemotherapy
|
September 4, 2016
Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients
Adrian Curran, Jhon Rojas, Alfonso Cabello, et al.
AIDS Research and Human Retroviruses
|
December 21, 2010
Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults
Elena Ferrer, Luis del Rio, Esteban Martínez, et al.
AIDS (London, England)
|
April 21, 2011
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent
Jing Yuan, Sheng Guo, David Hall, et al.
HIV Clinical Trials
|
August 28, 2007
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response
Daniel Podzamczer, Martin S King, Cheri E Klein, et al.
Antiviral Therapy
|
March 1, 2012
Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial
Adrian Curran, Esteban Martinez, Daniel Podzamczer, et al.
HIV Medicine
|
April 27, 2011
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study)
Daniel Podzamczer, J Andrade-Villanueva, B Clotet, et al.
The Journal of Antimicrobial Chemotherapy
|
December 20, 2014
Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial
José Moltó, Marta Valle, Elena Ferrer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 15, 2015
The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial
José R Santos, María Saumoy, Adrian Curran, et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology
|
May 25, 2021
Comparison of two sample collection devices for anal cytology in HIV-positive men who have sex with men: Cytology brush and Dacron swab
Ana C Silva-Klug, Maria Saumoy, Nuria Baixeras, et al.
AIDS (London, England)
|
January 27, 2007
Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients
Esteban Martínez, Juan A Arnaiz, Daniel Podzamczer, et al.
Page
of 19